Fact CheckerSign in

NCT03449953Active, not recruiting

Critical Care Outcomes of Hematologic Oncology Patients

Critical Care Outcomes of Patients With Hematologic Malignancy and Hematopoietic Cell Transplantation

Source: ClinicalTrials.gov · Last updated 27 Nov 2024

Brief summary (registry, in English)

Hematologic malignancy patients are admitted to ICU in increasing numbers. Successful ICU intervention has led to an increasing number of ICU survivors; however, there is a lack of information available about these patients' long term survival and quality of life. There is little Canadian data regarding ICU survival and regarding 1-year survival and functional outcomes in this group of patients. Over 500 patients are admitted annually to Canadian ICUs with an underlying hematologic malignancy or stem cell transplant, yet there is a paucity of up to date long-term outcome data. This information will facilitate a better understanding who would best benefit from critical care interventions and the impact of critical illness on their level of function at 1 year as well as survival.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
415 (actual)
First submitted
23 Nov 2017
Start date
26 Feb 2018
Primary completion date
31 Dec 2025
Lead sponsor
Mount Sinai Hospital, Canada
NCT number
NCT03449953

What you commit to

  • Study type: Observational
  • Participants enrolled: 415
  • From 26 Feb 2018 to the primary completion date, 31 Dec 2025
  • 13 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Subjects with significant preexisting neurological or psychiatric disease will be excluded from Phase 2 (1-year follow-up) but will be included in Phase 1.

Who the study is looking for

  • Subjects \>16 years with Hematologic Malignancy (HM) or post Stem Cell Transplant (HCT) who require ICU admission.
  • HM includes: acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myeloma, lymphoma, myelofibrosis, and other myeloproliferative disorders or myelodysplastic syndromes.
  • HCT is defined as the transplantation of multipotent hematopoietic stem cells from bone marrow, peripheral blood, or umbilical cord blood.

Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (13)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Foothills Hospital
Coordinator of this site? Confirm its status
CalgaryCanadaUnknown status
University of Alberta
Coordinator of this site? Confirm its status
EdmontonCanadaUnknown status
Queen Elizabeth II, Health Sciences Centre
Coordinator of this site? Confirm its status
HalifaxCanadaUnknown status
Juravinski Hospital
Coordinator of this site? Confirm its status
HamiltonCanadaUnknown status
Kingston General Hospital
Coordinator of this site? Confirm its status
KingstonCanadaUnknown status
Royal Victoria Hospital
Coordinator of this site? Confirm its status
MontrealCanadaUnknown status
Maisonneuve-Rosemont Hospital
Coordinator of this site? Confirm its status
MontrealCanadaUnknown status
Ottawa Hospital
Coordinator of this site? Confirm its status
OttawaCanadaUnknown status
Sunnybrook Health Sciences Centre
Coordinator of this site? Confirm its status
TorontoCanadaUnknown status
University Health Network
Coordinator of this site? Confirm its status
TorontoCanadaUnknown status
Mount Sinai Hospital
Coordinator of this site? Confirm its status
TorontoCanadaUnknown status
Vancouver General Hospital
Coordinator of this site? Confirm its status
VancouverCanadaUnknown status
University of Manitoba
Coordinator of this site? Confirm its status
WinnipegCanadaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.